| Abstrakt: |
Objective: This study aims to evaluate Omecamtiv Mecarbil (OM) therapeutic efficacy and adverse effects in heart failure Design: This article is a systematic review. Material and methods: This systematic review used the PRISMA approach with precise inclusion and exclusion criteria to collect articles from PubMed, Science Direct, DOAJ, and epistemonikos. From 175 database articles, 4 articles met inclusion criteria. Results: Heart failure affects the heart, muscles, kidneys, sympathetic nervous system, and neurohormonal alterations. This condition affects 23 million individuals worldwide, making it a major issue. Beta adrenergic receptor agonists and phosphodiesterase inhibitors enhance intracellular calcium to treat heart failure. Discussion: An overabundance of intracellular calcium can cause oxygen depletion, arrhythmias, hypotension, and death. Recent investigations reveal that omecamtiv mecarbil (OM) as a cardiac myosin activator has good efficacy and few side effects, making it a promising heart failure therapy. OM improved heart failure outcomes such as systolic ejection time, stroke volume, left ventricular diameter, heart failure incidence, dyspnea relief, and cardiovascular disease mortality. Conclusion: OM as a therapy for heart failure has improved result quality, therefore it could be a new therapy with few side effects. [ABSTRACT FROM AUTHOR] |
